Product Name:6-Bromo-3,4-dichloroquinoline

IUPAC Name:6-bromo-3,4-dichloroquinoline

CAS:927801-17-0
Molecular Formula:C9H4BrCl2N
Purity:97%
Catalog Number:CM260590
Molecular Weight:276.94

Packing Unit Available Stock Price($) Quantity
CM260590-250mg in stock ƥȺƿ
CM260590-1g 1-2 Weeks Ȑƛƛ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:927801-17-0
Molecular Formula:C9H4BrCl2N
Melting Point:-
Smiles Code:ClC1=C(Cl)C=NC2=CC=C(Br)C=C12
Density:
Catalog Number:CM260590
Molecular Weight:276.94
Boiling Point:
MDL No:
Storage:

Category Infos

Quinolines
Quinolines are an important class of biologically active heterocyclic compounds, and their derivatives usually exhibit a variety of biological activities. They can be used as antimalarial drugs and in the preparation of other antimalarial drugs. Other important activities of quinoline derivatives include inhibitory activity against EGFR-TK and antipsychotic activity. Futhermore, quinoline scaffolds are present in various drug molecules, including the antimalarial drugs aablaquine, chloroquine, mefloquine and primaquine, and the antibacterial agents gatifloxacin, levofloxacin, and moxifloxacin.
Quinoline Price
if you have any question on quinoline price, we will give the professional answers to your short questions.

Column Infos

Paltusotine
Crinetics’ once-daily oral paltusotine achieved the primary and all secondary endpoints in the phase 3 PATHFNDR-2 study in acromegaly patients.
Acromegaly is a serious rare disease generally caused by a pituitary adenoma, a benign tumor in the pituitary that secretes growth hormone (GH). Excess GH secretion causes excess secretion of IGF-1 from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications, often resulting in bone, joint, cardiovascular, metabolic, cerebrovascular, or respiratory disease. 
Paltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist and is currently in investigational Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome. 

Related Products